College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
 
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
 
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Reference Resources and Publications > CAP TODAY > CAP TODAY 2004 Archive > Anatomic Abstracts
Printable Version

  Anatomic Abstracts

title

 

 

 

cap today

March 2004

Anatomic pathology abstracts editors: Michael Cibull, MD, professor of pathology and laboratory medicine and director of surgical pathology, University of Kentucky Medical Center, Lexington, Subodh Lele, MD, assistant professor of pathology and laboratory medicine, University of Kentucky Medical Center, and Melissa Kesler, MD, hematopathology fellow, University of Texas Southwestern Medical Center at Dallas.


Relevance of occult axillary micrometastasis in ductal carcinoma in situ

Ductal carcinoma in situ represents 20 percent of newly diagnosed breast carcinoma cases. The incidence of axillary metastasis in DCIS historically has been small (one to two percent), and its significance has been debated. It is widely known that serial sections of lymph nodes coupled with keratin immunohistochemistry increase the identification of micrometastasis. The advent of sentinel lymph node evaluation underscores the need to re-evaluate the significance of occult micrometastases in DCIS. Patients with DCIS and negative axillary lymph nodes from 1974 to 1992 were selected from the Saint Barnabas Medical Center Tumor Registry for a study. All diagnoses were confirmed, and paraffin blocks were retrieved after subjects were accepted into the study. Seven serial sections were obtained from each block and evaluated with two cytokeratin immunohistochemistry stains. Clinical followup ranged from 10 to 28 years. The study was conducted with 102 patients. Micrometastases were identified in 13 patients (13 percent), mostly on one level and composed of microscopic clusters in the subcapsular sinus. Seven of these lymph node-positive patients (58 percent) had high-grade comedo DCIS, four (33 percent) had intermediate grades of various types of DCIS, and one had a low-grade micropapillary DCIS. The overall disease recurrence rate was 12 percent, but micrometastasis was not detected in any of the patients who developed disease recurrence. The authors concluded that serial immunohistochemistry evaluation of lymph nodes dramatically increases the identification of occult micrometastasis. Micrometastasis detected by immunohistochemistry, however, has no apparent clinical significance in DCIS based on the current long-term clinicopathologic study. The authors, therefore, question the significance of occult micrometastasis, identified by immunohistochemistry, in DCIS of any type and extent. Further evaluation and followup of lymph node micrometastases in patients with invasive tumors of various sizes are needed. The current findings would not support altering the stage of patients with DCIS and micrometastasis detected by immunohistochemistry alone.

Lara JF, Young SM, Velilla, RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003;98:2105–2113.

Reprints: Dr. Jonathan F. Lara, Dept. of Pathology, St. Barnabas Medical Center, 94 Old Short Hills Rd., Livingston, NJ 07039; jlara@sbhcs.com


A new classification scheme for the prognostic stratification of meningioma

Meningiomas are usually considered benign tumors, yet relapses, including histopathologically aggressive and benign tumors, occur in 10 to 20 percent of patients. The authors explored the value of numerical abnormalities for chromosomes 1, 9, 10, 11, 14, 15, 17, 22, X, and Y in meningiomas from 70 patients for predicting relapse-free survival. The presence of numerical abnormalities for one or more chromosomes was found in 77 percent of the patients. Chromosome 22 in the whole series and chromosome Y in males were the most frequently altered, followed by chromosomes 1, 14, and X in females. Abnormalities of chromosomes 1, 9, 10, 11, 14, 15, 17, the sex chromosomes, and gains of chromosome 22 were associated with adverse prognostic features, more frequent relapses, and shorter relapse-free survival rates. Multivariate analysis showed that tumor grade together with chromosome 14 status and age were the best combination of independent variables for predicting relapse-free survival rates. According to these variables, all patients with a score of two or who had more than two adverse prognostic factors had experienced relapse at five years, whereas none of those with a score of zero had experienced relapse 10 years after surgery. The authors concluded that in addition to age and histologic grade, abnormalities of chromosome 14 contribute to a better prognostic stratification of meningioma patients at diagnosis. Additional prospective studies in larger series of patients, including larger numbers of patients who experienced relapse, are necessary to confirm the utility of the proposed predictive model.

Maillo A, Orfao A, Sayagues JM, et al. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol. 2003;21:3285–3295.

Reprints: Dr. Angel Maillo, Servicio de Neurocirugia, Hospital Universitario de Salamanca, Paseo de San Vicente 58, 37007 Salamanca, Spain; a_maillo@yahoo.es


Confirming molecular classification of DLBCL by immunohistochemistry using a tissue microarray

Diffuse large B-cell lymphoma (DLBCL) can be divided on the basis of gene expression profiling, using a cDNA microarray, into three prognostically important subgroups: germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3. The GCB group has significantly better survival than the other two groups, and therefore identification of subgroups is of great clinical interest. Gene expression technology, however, is not widely available for routine clinical use. Furthermore, it is expensive and requires fresh or frozen tissue. The authors evaluated the use of immunohistochemistry to predict subgroups in DLBCL, correlating their results with results of cDNA microarray gene-expression data. They created tissue microarray blocks from 152 cases of DLBCL, 142 of which had been previously evaluated by cDNA microarray. Sections were stained with antibodies to CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2. The authors then subclassified cases based on expression of CD10, bcl-6, and MUM1 into GCB and non-GCB subgroups. Forty-two percent of the cases were considered GCB, and 58 percent were considered non-GCB. The five-year overall survival rate for the GCB group was 76 percent, while that for the non-GCB group was only 34 percent (P<.001), similar to data on overall survival reported using the cDNA microarray. Furthermore, the tissue microarray immunostain panel reproduced the cDNA microarray classification—GCB versus non-GCB—in approximately 80 percent of cases. In cases with discrepant classification, the overall survival rate was predicted better using the tissue microarray. In multivariate analysis, a high International Prognostic Index score of three to five and the non-GCB phenotype were independent adverse predictors (P<.0001) of survival. These results suggest that a relatively limited immunostaining panel can be used to determine the GCB and non-GCB subgroups of DLBCL and to predict survival similar to the cDNA microarray.

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.

Reprints: Dennis D. Weisenburger, Dept. of Pathology and Microbiology, 983135 Nebraska Medical Center, Omaha, NE 68198; dweisenb@unmc.edu


Ability to assess the histopathologic prognostic variables in primary cutaneous melanoma

The prognosis for patients with localized primary cutaneous melanoma depends principally on tumor thickness and to a lesser extent on ulcerative state and Clark level. The authors recently found in an analysis of 3,661 patients that tumor mitotic rate is also an important prognostic parameter, ranking second to tumor thickness. However, few studies have assessed the accuracy and reproducibility with which these features of a melanoma are recorded by histopathologists. The authors of the present study assessed the interobserver reproducibility of major pathologic prognostic parameters in cutaneous melanoma. Single hematoxylin and eosin-stained slides of 69 dermally invasive primary cutaneous melanomas were circulated among six pathologists who had different experiences in assessing melanocytic tumors. The observers independently determined the tumor thickness, Clark level of invasion, ulcerative state, and tumor mitotic rate for each lesion. They calculated intraclass correlation coefficients and kappa scores for multiple ratings per subject. The intraclass correlation coefficients were 0.96 for tumor thickness and 0.76 for tumor mitotic rate. The kappa scores were 0.83 for ulcerative state and 0.60 for Clark level. These results indicated excellent agreement among the pathologists for measuring tumor thickness, ulcerative state, and tumor mitotic rate and fair to good agreement for Clark level. The authors concluded that appropriately trained and experienced histopathologists can assess prognostically important features of melanomas accurately and reproducibly. Given recent findings of the significance of tumor mitotic rate in determining prognosis, it is important that this feature be assessed by a standardized method and documented for all primary cutaneous melanomas.

Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003; 27:1571–1576.

Reprints: Richard A. Scolyer, Dept. of Anatomical Pathology, Royal Prince Alfred Hospital, Missenden Rd., Camperdown, NSW 2050 Australia; richard. scolyer@ email.cs.nsw.gov.au


Tumor size predicts survival within stage IA non-small cell lung cancer

It has been demonstrated that patients with stage I lung cancer have improved five-year survival rates. This observation has stimulated interest in lung cancer screening programs in an effort to detect smaller and potentially more curable tumors. The authors conducted a study in which they retrospectively analyzed patients with pathologically confirmed stage IA non-small cell lung cancer resected at their institution between 1991 and 2001. Kaplan-Meier survival analysis was performed to estimate the five-year overall and disease-specific survival probability stratified by tumor size. The effects of age, gender, histology, and tumor size on survival were also analyzed using a Cox proportional hazards regression model. The authors identified 244 patients (median followup, 2.6 years). Of these, 229 received lobectomy, eight segmentectomy, and seven wedge resection. Histologic diagnoses included adenocarcinoma (59.4 percent), squamous cell carcinoma (18.9 percent), bronchioloalveolar (15.2 percent), large cell (4.5 percent), and poorly differentiated (2.0 percent). The five-year survival probability for all patients was 71.1 percent. For patients with tumors of 2 cm or less, the five-year probability of survival was 77.2 percent, compared with 60.3 percent for patients with tumors larger than 2 cm. The overall five-year disease-specific survival was 74.9 percent. For patients with tumors of 2 cm or less, it was 81.4 percent, compared with 63.4 percent for patients with tumors larger than 2 cm. The authors concluded that, even within the confines of stage IA cancer, there appear to be differences in survival rates based on tumor size. They suggest that further substaging be considered.

Port JL, Kent MS, Korst RJ, et al. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest. 2003;124:1828–1833.

Correspondence: Dr. Nasser Altorki, Dept. of CT Surgery, Ste. M404, Weill Medical College of Cornell University, 525 E. 68th St., New York, NY, 10021


Histopathological parameters as predictors for the course of Crohn’s disease

Recent classification systems discriminate penetrating Crohn’s disease from stricturing and nonstricturing/nonpenetrating CD, however, no easily detectable marker has yet been identified that can predict the course of CD. Individual, clinical course-specific new treatment schemes would be highly desirable for different potentially divergent pathophysiological pathways—for example, fistula versus stenosis. The authors retrospectively studied intestinal tissue biopsies from 63 CD patients with disease followup of up to seven years. In the biopsy specimens, 34 histopathological features present prior to the onset of strictures or fistulas were evaluated and compared with biopsies from patients with nonstricturing/ nonpenetrating disease. Five histomorphological parameters demonstrated significant associations to different disease courses when applying univariate analysis. In a multivariate logistic regression model, the best predictors of an uncomplicated disease course were severe lymphocytic infiltration of the lamina propria, presence of crypt atrophy, and absence of lymphocytic infiltration of the epithelium. The combination of these parameters has a sensitivity of 67 percent and a specificity of 83 percent for predicting nonstricturing/nonpenetrating disease (positive predictive value, 0.75). The authors concluded that histopathological parameters may help to predict complications of CD prior to its onset, but the results of this study have to be confirmed prospectively.

Bataille F, Klebl F, Rümmele P, et al. Histopathological parameters as predictors for the course of Crohn’s disease. Virchows Arch. 2003;443:501–507.

Reprints: F. Bataille, Dept. of Pathology, University of Regensburg, 93042 Regensburg, Germany; frauke.bataille@ klinik.uni-regensburg.de


Causes of hepatic granulomas

Epithelioid granulomas have been reported in two to 15 percent of unselected liver biopsies, and numerous underlying etiologies have been described. However, all United Kingdom series were reported before hepatitis C virus was identified. The authors evaluated the current etiologies of hepatic granulomas and assessed the prognosis for the “idiopathic” group, in which all investigations for a recognized cause were negative or normal. The authors conducted a retrospective review of patient case notes between 1991 and 2001. All patients who had a liver biopsy at Glasgow Royal Infirmary that revealed epithelioid granulomas had their case notes and liver biopsies reviewed and a standard proforma completed. Of the 1,662 liver biopsies performed during the study period, hepatic granulomas were found in 63 patients, 47 of whom were female and a mean age of 42 years (range, 17 to 81 years). The underlying etiologies were primary biliary cirrhosis (PBC; 23.8 percent), sarcoidosis (11.1 percent), idiopathic (11.1 percent), drug induced (9.5 percent), HCV (9.5 percent), PBC/autoimmune hepatitis (AIH) overlap (6.3 percent), Hodgkin lymphoma (6.3 percent), AIH (4.8 percent), tuberculosis (4.8 percent), resolving biliary obstruction (3.2 percent), and other single miscellaneous causes (9.5 percent). Of the seven patients with idiopathic hepatic granulomas, one was lost to followup, one died of stroke, and the remaining five were well with no liver-related morbidity at a mean followup of 6.2 years. The authors noted that the etiology of hepatic granulomas is broad, and HCV is an important cause in this population. Despite extensive investigations, 10 to 15 percent of patients still had idiopathic hepatic granulomas. The prognosis for this group, however, appears to be excellent.

Gaya DR, Thorburn D, Oien KA, et al. Hepatic granulomas: a 10-year single centre experience. J Clin Pathol. 2003;56:850–853.

Reprints: Dr. D. Gaya, 15 Julian Ave., Kelvinside, Glasgow, G12 ORB, United Kingdom; danielgaya@aol.com

   
 

 

 

   
 
 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed